Akeso, Inc.: history, ownership, mission, how it works & makes money

Born in 2012 when Dr. Xia Yu and three co‑founders launched Akeso with an initial VC cheque of $3 million, the company rapidly built credibility through a 2015 licensing deal with Merck for Quavonlimab, went public on the HKEX in April 2020 as 9926.HK, and accelerated global ambitions with an October 2024 placement of roughly HK$1.924 billion (about $250 million) to fund clinical expansion; by April 2025 its PD‑1 antibody Penpulimab secured FDA approval, propelling a market capitalization that reached approximately HK$107.96 billion by December 2025, supported by ~921.14 million shares outstanding with insiders holding 18.14% and institutions 29.22%; Akeso now runs the ACE and Tetrabody technology platforms, advances a pipeline of over 20 investigational drugs (nine in clinical stages), and combines commercial sales-net sales rose 49.20% to RMB1,401.6 million in H1 2025-with licensing income (e.g., RMB121.6 million from Summit Therapeutics in 2024), placement proceeds, milestone payments and royalties to underwrite R&D despite a reported net loss of RMB501.1 million in 2024.

Akeso, Inc. (9926.HK): Intro

• Founding: 2012 by Dr. Xia Yu and three co-founders; initial VC funding ≈ $3 million.
• Key early partnership: 2015 licensing agreement with Merck & Co. for Quavonlimab (enhanced credibility and global validation).
• IPO: Listed on the Hong Kong Stock Exchange in April 2020 under ticker 9926.HK.
• Capital raise: October 2024 share placement ≈ $250 million USD; ~70% of proceeds directed to accelerating global clinical development.
• U.S. approval: April 2025 - FDA approval of Penpulimab (PD‑1 monoclonal antibody), Akeso's first U.S. product approval.
• Market capitalization: As of December 2025 ≈ HK$107.96 billion.

• Founders & management: ~15% (including Dr. Xia Yu and executive team equity holdings and options).
• Institutional investors (long‑only and strategic biotech investors): ~45%.
• Public/free float (retail and other investors): ~35%.
• Employee option pool/others: ~5%.

• Mission: Develop best‑in‑class antibody therapeutics and combination regimens to improve survival and quality of life for cancer and autoimmune patients globally.
• R&D model: In‑house discovery and development of biologics with selective out‑licensing and partnerships for regional commercialization and late‑stage development.
• Clinical focus: PD‑1 programs (e.g., Penpulimab), bispecific antibodies, and next‑generation immune modulators; emphasis on global registration trials.

• Discovery & preclinical: Internal research teams generate monoclonal and bispecific candidates.
• Clinical development: Phased clinical trials (China, U.S., global) with a strategy to secure regional approvals and global labeling.
• Partnerships & licensing: Strategic partnerships (e.g., Merck deal for Quavonlimab in 2015) to monetize assets via upfronts, milestones, and royalties.
• Manufacturing & supply: Hybrid model using in‑house capabilities plus CMOs for scale production to support global launches.
• Commercialization: Combination of direct commercialization in select markets and out‑licensing or co‑promotion in others.

• Product sales - marketed biologics (e.g., after Penpulimab U.S. approval): direct oncology and hospital sales.
• Licensing income - upfront payments, development and regulatory milestones, and tiered royalties from partners (historically demonstrated by 2015 Merck licensing of Quavonlimab).
• Research collaborations & grants - funding from strategic partners and public/private grants supporting trials.
• Capital markets activity - equity raises (e.g., Oct 2024 $250M placement) to fund expensive late‑stage trials and commercial preparation; impacts cash runway and dilution.

Akeso, Inc. (9926.HK): History

• Founded: early-stage biotech with emphasis on oncology/immunology biologics.
• Listing: publicly listed on the Hong Kong Stock Exchange (9926.HK) to fund late-stage trials and commercialization.
• Pipeline growth: progressed multiple candidates through Phase 1-3 trials and expanded global partnerships and licensing.

• Insiders (executives, employees): 18.14% - aligns management incentives with long-term value creation.
• Institutional investors: 29.22% - significant participation from large funds provides stability and analytical coverage.
• Public holders/free float: remaining shares (~52.64%) - supply liquidity for trading and capital access.

• Core mission: develop and commercialize targeted biologic therapies to improve outcomes in oncology and immune-mediated diseases.
• Strategic priorities: advance clinical development, secure regulatory approvals, scale manufacturing, and pursue selective global partnerships.

• R&D and clinical development: investment in discovery, preclinical studies, and multi-phase clinical trials to create proprietary biologics.
• Revenue streams:
  • Product sales - from commercialized therapeutics once approved.
  • License and collaboration fees - milestone payments and royalties from partners.
  • Research collaborations and grant income - co-development agreements that offset R&D costs.
• Capital strategy: equity markets (HKEX listing) and institutional support fund expensive late-stage trials and manufacturing scale-up.
• Value drivers: clinical trial success rates, regulatory approvals, pricing/reimbursement, and partnership/licensing deals.

Akeso, Inc. (9926.HK): Ownership Structure

• Mission: Develop innovative antibody drugs that are affordable to patients worldwide, focusing on oncology, autoimmune, and metabolic diseases.
• Patient-centric approach: Prioritizes unmet medical needs, safety, and data integrity across clinical programs.
• Ethical standards: Commits to high ethical conduct in trials and business operations, ensuring robust compliance and transparent reporting.
• Collaboration: Partners with leading pharmaceutical and biotech companies to accelerate R&D and expand global reach.
• Sustainability & social responsibility: Implements initiatives to reduce environmental impact and support community health access.
• Continuous innovation: Fosters scientific excellence and creativity to drive pipeline advancement and platform technologies.

• Clinical-stage pipeline monetization: milestone and royalty payments from strategic partnerships and out-licensing.
• Direct product sales (as lead candidates reach market): revenue from proprietary antibody therapeutics targeting oncology and other indications.
• R&D collaborations: upfront payments, co-development funding, and cost-sharing arrangements with global pharma partners.
• Capital markets access: equity raises on HKEX (9926.HK) and potential follow-on offerings to fund late-stage trials and commercial expansion.
• Grants and subsidies: targeted public funding for biotech innovation and local clinical trial support.

Akeso, Inc. (9926.HK): Mission and Values

• ACE Platform: a comprehensive in-house platform covering target validation, antibody discovery, lead optimization, preclinical pharmacology, and translational biomarker development to move candidates efficiently from concept to IND.
• Tetrabody Technology Platform: a proprietary bi-specific and multi-specific antibody engineering system that enables creation of next‑generation therapeutics with optimized affinity, half-life, and functional formats for oncology and immune-mediated diseases.
• GMP-compliant manufacturing: in-house biologics manufacturing capabilities that meet international GMP standards, enabling clinical and commercial supply continuity and tighter control over CMC timelines and costs.

• Pipeline breadth: over 20 innovative investigational drugs in discovery and development; nine candidates have entered clinical stages (Phase 1-3), concentrated on oncology and autoimmune indications.
• Global clinical footprint: trials conducted across Greater China, the United States, Southeast Asia, and select European centers to support global regulatory filings and broaden patient access.
• Strategic partnerships: select out‑licensing and co-development arrangements to accelerate late‑stage trials and expand commercial channels in overseas markets.

• Quality systems: robust quality control and assurance programs aligned with international standards to ensure product safety, purity, potency, and consistency prior to clinical use and commercialization.
• Regulatory approach: clinical protocols and manufacturing dossiers prepared to meet multiple regulatory authorities (e.g., NMPA, FDA, EMA) to enable global approvals where applicable.
• R&D intensity: a significant portion of resources is allocated to R&D to sustain pipeline growth and platform enhancement; the company consistently reinvests revenues and capital into discovery and development activities.

• Platform-enabled candidate generation that increases probability of clinical success and shortens timelines versus outsourced discovery.
• Bi‑specific/Tetrabody assets that can address resistant tumors and combination therapy niches with higher differentiation.
• Control of CMC and supply via in-house GMP facilities, reducing dependency risk and supporting faster scale-up upon approval.

Akeso, Inc. (9926.HK): How It Works

• Commercial product sales - primary and growing revenue source driven by marketed antibody drugs; net sales rose 49.20% to RMB 1,401.6 million in 1H 2025.
• Licensing and collaboration income - upfront/licence fees and program-specific payments such as the RMB 121.6 million received from Summit Therapeutics in 2024.
• Milestones and royalties - potential milestone receipts and ongoing royalties from out‑licensed assets and co‑development partners.
• Capital raises - equity placements to finance R&D and expansion (e.g., HK$1.924 billion raised in October 2024).

• Commercialization: Akeso advances candidates through clinical development to market, then captures revenues via direct sales of marketed antibodies (hospital and oncology channels, specialty clinics).
• Out‑licensing & partnerships: Discovery or mid‑stage assets may be licensed to global pharma/biotech partners for upfront fees, development funding, and downstream royalties.
• Milestone structure: Strategic deals typically include staged milestone payments tied to clinical, regulatory and sales milestones that can materially boost cash flow when achieved.
• Capital management: Periodic equity placements and possible debt facilities provide near‑term funding for expensive late‑stage trials and commercial scale‑up.
• Reinvestment strategy: Operating cash and proceeds are primarily reinvested into R&D to broaden the antibody pipeline and support international commercialization.

Akeso, Inc. (9926.HK): How It Makes Money

• Commercial sales of approved biologics (domestic and, since Apr 2025, U.S. sales following FDA approval of penpulimab).
• Out-licensing and collaboration revenues (milestone payments, royalties, and co-promotion fees) from international partners.
• R&D service income and manufacturing contracts leveraging in-house biologics capabilities.
• Equity investments and strategic partnerships that can produce gains - though 2024 saw losses from such investments.

• Pipeline depth (20+ candidates, 9 clinical) supports multiple future launch opportunities and diversified revenue potential.
• International trials and partnerships aim to de-risk launches and accelerate market penetration across Asia, Europe, and the U.S.
• Short-term profitability is pressured by R&D investment; medium-term upside hinges on successful commercial rollouts and partnerships.